Rubinstein Samuel
Known title: DirectorCIK: 0001742152
Rubinstein Samuel's purchase track record
Rubinstein Samuel has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/1/2026 | MDWD | $7K | pending | pending | — |
| 5/29/2026 | MDWD | $2K | -11.6% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| MDWD | ▼ Sell | Open Market | 525 | $7K | 9/1/2026 | View on chart |
| MDWD | ▲ Buy | Open Market | 525 | $7K | 9/1/2026 | View on chart |
| MDWD | ▲ Buy | Open Market | 150 | $2K | 5/29/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
MediWound Secures $3.3M U.S. Department of War Grant
MediWound has been awarded an additional $3.3 million by the U.S. Department of War. The funding is intended to advance the development of a room-temperature-stable formulation of its NexoBrid product. This grant supports the company's ongoing research efforts for its lead therapeutic asset.
MediWound Secures $3.3M U.S. Department of War Grant. MediWound has been awarded an additional $3.3 million by the U.S. Department of War. The funding is intended to advance the development of a room-temperature-stable formulation of its NexoBrid product. This grant supports the company's ongoing research efforts for its lead therapeutic asset.